利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

803 条记录 (耗时 0.027 秒)

    CELLULAR ANALYSIS OF BODY FLUIDS
    3.
    发明授权
    CELLULAR ANALYSIS OF BODY FLUIDS 有权
    体液的细胞分析

    公开(公告)号：EP2798087B1

    公开(公告)日：2018-03-07

    申请号：EP12862848.4

    申请日：2012-12-19

    申请人： ABBOTT LABORATORIES

    发明人： WU, Jiong ,  LIN, Emily, H. ,  YANG, Jihping

    IPC分类号： C12Q1/68 ,  G01N33/48 ,  C12M3/00 ,  G01N1/10

    CPC分类号： C12Q1/04 ,  G01N33/5094

    摘要： Herein is provided a simple, reliable and accurate method for cellular analysis on hematology analyzers. In various aspects, the methods provide separation and/or differentiation between red blood cells (RBCs) and white blood cells (WBCs) by utilizing a fluorescent dye to selectively stain WBCs such that they emit stronger fluorescence signals. The method provides optimal detection limits on WBCs and RBCs, thereby allowing analysis of samples with sparse cellular concentrations. As few as one reagent may be used to prepare a single dilution for body fluid analysis, in order to simplify the body fluid analysis. Minimal damage to WBCs is attained using the lysis-free approach described in aspects of the disclosure.

    BLOOD TEST METHOD
    5.
    发明授权
    BLOOD TEST METHOD 有权
    血液测试方法

    公开(公告)号：EP3064941B1

    公开(公告)日：2017-12-06

    申请号：EP16158013.9

    申请日：2016-03-01

    申请人： ARKRAY, Inc.

    发明人： Nakamura, Tsutomu

    IPC分类号： G01N33/49 ,  G01N33/50 ,  G01N33/84

    CPC分类号： G01N33/5094 ,  G01N33/492 ,  G01N33/84

    摘要： The present invention provides a blood test device configured to measure a blood count and an electrolyte in a blood sample. The blood test device includes: a sample placement section in which a blood sample containing an anticoagulant containing a salt of ethylenediaminetetraacetic acid (EDTA) other than sodium salt, potassium salt, or calcium salt of EDTA is placed; and a measurement section by which measurement of a blood count and an electrolyte is carried out for the blood sample placed in the sample placement section.

    Blood analyzer, blood analysis method, hemolytic agent and staining agent
    6.
    发明授权
    Blood analyzer, blood analysis method, hemolytic agent and staining agent 有权
    血液分析仪，血液分析方法，溶血剂和染色剂

    公开(公告)号：EP2889620B1

    公开(公告)日：2017-10-11

    申请号：EP14198316.3

    申请日：2009-04-28

    申请人： Sysmex Corporation

    发明人： Matsumoto, Hideaki ,  Uchihashi, Kinya ,  Itose, Yuji ,  Konishi, Aya ,  Yoshida, Ayumu

    IPC分类号： G01N33/50 ,  G01N33/569

    CPC分类号： C12Q1/68 ,  G01N33/5094 ,  G01N33/56905 ,  G01N2333/44 ,  Y02A50/58

    摘要： This blood analyzer includes a sample preparation portion preparing a first measurement sample containing a blood sample and a hemolytic agent and a second measurement sample containing the blood sample, the same hemolytic agent as the hemolytic agent and a staining agent and a control portion classifying white blood cells in the first measurement sample into at least four groups of monocytes, neutrophils, eosinophils and a group of the others on the basis of fluorescent information and two types of scattered light information generated by a light information generation portion and classifying blood cells in the second measurement sample into malaria-infected red blood cells and a group of the others on the basis of fluorescent information and scattered light information generated by the light information generation portion.

    IDENTIFYING PATIENT RESPONSE TO S1P RECEPTOR MODULATOR ADMINISTRATION
    7.
    发明公开
    IDENTIFYING PATIENT RESPONSE TO S1P RECEPTOR MODULATOR ADMINISTRATION 审中-公开

    公开(公告)号：EP3199947A3

    公开(公告)日：2017-09-13

    申请号：EP17157993.1

    申请日：2013-04-19

    申请人： Novartis AG

    发明人： BORELL, Hubert ,  GARDIN, Anne ,  JIN, Yi ,  LEGANGNEUX, Eric ,  UFER, Mike

    IPC分类号： G01N33/50 ,  C12Q1/68 ,  G01N33/569

    CPC分类号： C07D205/04 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/5094 ,  G01N33/56972 ,  G01N2800/52

    摘要： The invention provides a method of assessing the appropriate therapeutic dose of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3- carboxylic acid to administer to a patient in need thereof, comprising the steps of:
    (i) testing whether or not the patient has the poor metabolizer genotype; and
    (ii) if the patient does not have the poor metaboliser genotype, administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at the standard therapeutic dose; and
    (iii) if the patient does have the poor metaboliser genotype, either
    (a) administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at a therapeutic dose below that of the standard therapeutic dose; or
    (b) not administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient.